Karin Haraldsson

BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease.

Å. Borg, N. Loman, O. Johannsson, 1998, Cancer research.

BRCA1 and BRCA2 mutation analysis in breast‐ovarian cancer families from northeastern Poland

Å. Borg, J. Limon, U. Johansson, 2003, Human mutation.

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

K. Stegmaier, M. Hemann, Å. Borg, 2015, Oncogene.

Directed evolution of chemotaxis inhibitory protein of Staphylococcus aureus generates biologically functional variants with reduced interaction with human antibodies.

S. Lindman, K. Haraldsson, J. V. van Strijp, 2010, Protein engineering, design & selection : PEDS.

Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.

P. Møller, Å. Borg, N. Loman, 2001, Human molecular genetics.

BRCA2 mutations in 154 finnish male breast cancer patients.

Anssi Auvinen, A. Auvinen, K. Waltering, 2004, Neoplasia.

Purification of truncated and mutated Chemotaxis Inhibitory Protein of Staphylococcus aureus--an anti-inflammatory protein.

S. Lindman, K. Haraldsson, E. Gustafsson, 2009, Protein expression and purification.

Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer

A. Lindblom, M. Stenmark-Askmalm, B. Arver, 2023, BMC Cancer.

A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes

Heli Nevanlinna, Therese Sandberg, Dietrich A. Stephan, 2002, Human Genetics.